There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sarepta Therapeutics (SRPT) and Orthofix (OFIX) with bullish sentiments.
Sarepta Therapeutics (SRPT)
In a report released today, Alethia Young from Cantor Fitzgerald maintained a Buy rating on Sarepta Therapeutics, with a price target of $217. The company’s shares closed yesterday at $141.49.
Young said:
“. Today’s update from Solid Biosciences’s (SLDB, NC) should be a positive competitive read to Sarepta and we would expect SRPT to trade up significantly (up 20%+) on today’s news, as the first of two competitor updates in 1H 2019 passes. Today Solid announced preliminary 3-month biopsy data in the first three patients dosed with its SGT-001 micro-dystrophin gene therapy. We continue to view Sarepta as a top pick, and we think investors continue to underestimate the limb girdle gene therapy program and market opportunity and see more upside even after today’s move.”
According to TipRanks.com, Young is a 4-star analyst with an average return of 5.1% and a 47.6% success rate. Young covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Vertex Pharmaceuticals, and Puma Biotechnology.
Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $197, a 39.2% upside from current levels. In a report issued on January 30, Piper Jaffray also maintained a Buy rating on the stock with a $200 price target.
See today’s analyst top recommended stocks >>
Orthofix (OFIX)
In a report released today, Craig Bijou from Cantor Fitzgerald maintained a Buy rating on Orthofix, with a price target of $60. The company’s shares closed yesterday at $57.74.
Bijou wrote:
“We maintain our Overweight rating and 12-month PT of $60 on OFIX. OFIX has transformed its Spine Fixation business over the last few years and combined with OFIX’s biologics business, the recent acquisition of Spinal Kinetics and internal product development, we think OFIX is well-positioned to expand its distribution and accelerate top-line growth. Valuation Summary We base our 12-month price target of $60 on a 11x EV/EBITDA multiple on our 2020 EBITDA estimate. Our price target is under review.”
According to TipRanks.com, Bijou is a 3-star analyst with an average return of 2.3% and a 55.6% success rate. Bijou covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Ra Medical Systems Inc, and Integra Lifesciences.
Orthofix has an analyst consensus of Moderate Buy, with a price target consensus of $63.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
